Menu

Drought-tolerant corn trials underwater

Agribusiness giant Monsanto is finding out that it's difficult to conduct field trials of drought-resistant corn when it won't stop raining. The company hopes to launch a new line of corn seed that's been genetically engineered to thrive in drough conditions by 2013.

May 26, 2011
Bob Grant

CornAGRILIFETODAY, FLICKRAgribusiness giant Monsanto is finding out that it's difficult to conduct field trials of drought-resistant corn when it won't stop raining. The company hopes to launch a new line of corn seed that's been genetically engineered to thrive in drought conditions by 2013, with plans to distribute it royalty-free to impoverished African farmers. But rainy summers since 2008 in the US western Plains, where Monsanto is conducting field trials of the seed, have muddied results. "We had about three good years where we could do field trials in Kansas. It was nice and dry," Monsanto regulatory affairs manager Bill Reeves told the Des Moines Register. "And then it started raining."

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!